PharmAbcine signs manufacturing agreement with Binex

▴ PharmAbcine signs manufacturing agreement with Binex
PharmAbcine signs long-term contract manufacturing organization agreement for Olinvacimab with Binex

PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigational Olinvacimab (TTAC-0001), PharmAbcine's leading antibody therapeutics pipeline in oncology.

Under the agreement, Binex is responsible for large-scale manufacturing of clinical investigational material for PharmAbcine for its global Phase 2 trials on olinvacimab + immunotherapy combination for metastatic triple negative breast cancer (the U.S. included) and trials on various common solid tumors. Binex has been a clinical manufacturing partner of PharmAbcine since early global clinical trials on olinvacimab.

"Contract manufacturing organization agreement with Binex enables us to secure the steady supply of investigational material for multinational clinical trials and trials on various common solid tumors. We will remain fully committed to the swift development of olinvacimab in use for the treatment of recurrent glioblastoma multiforme (rGBM) and metastatic triple-negative breast cancer (mTNBC)," said Jin-san Yoo, GM, PharmAbcine.

Olinvacimab, an anti-vascular endothelial growth factor receptor 2 (VEGFR2), targets and inhibits tumor angiogenesis-inducing VEGFR2. PharmAbcine is conducting a Phase 2 clinical trial on olinvacimab in patients with Avastin-refractory rGBM in the U.S. and Australia. In addition, Phase 1b trials on olinvacimab plus PD-1 antibody Keytruda (pembrolizumab) combination for rGBM and mTNBC are still going on in Australia in collaboration with MSD (Merck).

PharmAbcine gave an update about how far the development of olinvacimab had come at the world's largest conference of the pharmaceutical and biotechnology industry '2020 Bio International Convention' hosted virtually from 8th till 12th. It is working with multiple pharmaceutical and biotech companies to further discuss olinvacimab technology transfer.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.

PharmAbcine's leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is currently in a phase II study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients in both US and Australia. In collaboration with MERCK, olinvacimab plus pembrolizumab Phase Ib trials for mTNBC and rGBM are on-going.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With its highly advanced technology platforms, it provides high-quality antibody generation services. The high standards have allowed PharmAbcine to expand co-development opportunities with not only existing but also potential partners.

On the other hand, Binex Co., Ltd. is a publicly-traded specialized pharmaceutical company located in Busan, Korea developing a broad range of pharmaceutical products such as nutrients and vitamin compounds, and intestinal antiseptic concentrated with probiotics screened by Binex. Binex is also developing a strong anti-cancer franchise based around their DC-Vac and ANY CELL cell bank businesses. BINEX went public in 2001 on the Korean Stock Exchange and recorded sales of $30 million in the 2007 fiscal year.

Tags : #PharmAbcine #Binex #olinvacimab #ContractManufacturing #Korea #Busan

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

No health, gender and economic justice without ending wars, invasions and genocidesJuly 19, 2025
Venus Remedies Secures WHO GDP Endorsement for Best-in-Class Pharma LogisticsJuly 18, 2025
Single Surgeon Performs 17 Joint Replacements in 8 Hours at CARE Banjara, Setting New Benchmark in Orthopedic ExcellenceJuly 17, 2025
Sterling Hospitals Rajkot Achieves a Medical Milestone: Successfully Treats Rare and Life-Threatening Heart Condition RSOV Without Open Heart SurgeryJuly 17, 2025
Vidyadhan Alumni and Students Successfully Host Third Annual Blood Donation DriveJuly 17, 2025
HOSMAC Signs MoU with Gulf Medical University as Industry Partner to Strengthen Healthcare Education and CollaborationJuly 17, 2025
Why Teens Can’t Wake Up Early: The Hidden Problem of School TimingsJuly 17, 2025
Code Blue to Code Smart: How AI is Reshaping ICU Risk StratificationJuly 17, 2025
TERN Group Launches Its 7th Training Centre - and First Dedicated to Japanese Language & Careers - in GuwahatiJuly 16, 2025
Sri Sathya Sai Heart Hospital Ahmedabad and Rajkot signed an MOU with Gujarat Health Department for free heart surgery for needy children and adults July 16, 2025
No health without rights, says Shobha Shukla SDG-3 Lead Discussant at UN meetJuly 15, 2025
30 Minutes To Freedom, Robotic Surgery Ends 89-YO’s Swallowing NightmareJuly 15, 2025
Himalaya Wellness Champions Bhringaraja in New Anti-Hair Fall Campaign with a Tale of FriendshipJuly 15, 2025
ViiV Healthcare and Medicines Patent Pool extends voluntary licensing agreement to enable access to long-acting injectable HIV treatment July 15, 2025
Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025